FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments

This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY

Read more »

Labels: Aubagio, Betaseron, Copaxone, Gilenya, Lemtrada, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri

Biogen Idec inc Earnings Were Great. Here's Why the Stock Tumbled Anyway

There's nothing like the disclosure of a side effect to ruin a perfectly good earnings report. Despite meeting analyst expectations on revenue, and beating on the earnings-per-share side, Biogen Idec traded down more than 10% at one point today after announcing that a patient taking its oral multiple sclerosis drug Tecfidera contracted progressive multifocal leukoencephalopathy, or PML.
Read more »

Labels: Biogen, PML (Progressive Multifocal Leukoencephalopathy), TECFIDERA, Tysabri

Plegridy approved by FDA for multiple sclerosis

The U.S. Food and Drug Administration (FDA) has approved Plegridy as the new multiple sclerosis treatment by Biogen Idec.
Read more »

Labels: Plegridy, TECFIDERA, Tysabri

Multiple sclerosis: What you need to know about the disease

Read more »

Labels: Betaseron, Copaxone, Novantrone, Rebif, Tysabri

Can Biogen Idec Take Wing With Tecfidera?

Biogen Idec (NASDAQ:BIIB) generates most of its revenue from drugs for MS (multiple sclerosis), but also receives substantial sums from other disease indications. It recently has gained approval for its hemophilia therapies. Biogen has a high trailing P/E ratio, (38, at $342 per share) consistent with investors expecting continued EPS growth.
Read more »

Labels: Rituxan, TECFIDERA, Tysabri

MSNZ welcomes consultation period for Tysabri and Gilenya

Read more »

Labels: Betaseron, Copaxone, Gilenya, Tysabri

GOOD NEWS ON TEVA'S NEW MS TREATMENT LAQUINIMOD (NERVENTRA)

Read more »

Labels: Betaseron, Copaxone, Gilenya, Laquinimod (Nerventra), Novantrone, Rebif, Tysabri

Biotech Gets A Lift On Popular Drug, Strong Pipeline

The success of Biogen Idec's oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder.
Read more »

Labels: Biogen, Rituxan, TECFIDERA, Tysabri

Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR

Teva soaring out in front on a single product and it is no surprise that the Generics pack are waiting in the rear ready for the copaxone patents to expire starting May 2014. However Biogen are backing the most winners with a staggering $5.8 billion worth of business. 

#1 Glaterimer acetate Teva     $4.3 billion
#2 Avonex Biogen Idec           $3.0 billion
#3 Gilenya Novartis                 $1.9 billion
#4 Tysabri Biogen  Idec           $1.7 billion
#5 Betaseron Bayer                 $1.1 billion
#6 Tecfidera Biogen Idec        $0.9 billion
#7 Rebif EMD serono              $0.6 billion
#8 Ampyra Biogen Idec           $0.3 billion
#9 Aubagio Sanofi                   $0.2 billion
#10 Extavia Novartis               $0.2 billion
Read more »

Labels: 20 Best Stories & Studies, Ampyra, Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Rebif, TECFIDERA, Tysabri

Biogen profit rises as Tecfidera shines

Read more »

Labels: Biogen, TECFIDERA, Tysabri

Biogen Idec to Present New Clinical Data from Its Neurology Portfolio of Drugs at AAN Annual Meeting

Read more »

Labels: Ampyra, Biogen, TECFIDERA, Tysabri

Multiple Sclerosis and Pregnancy: Current Considerations

Read more »

Labels: Betaseron, Copaxone, Gilenya, Pregnancy, Rebif, Tysabri

Can new versions of Copaxone, Avonex drive market share retention?

Read more »

Labels: Copaxone, TECFIDERA, Tysabri

HOW MS MEDICATIONS DIFFER FROM EACH OTHER

Read more »

Labels: Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, Rebif, TECFIDERA, Tysabri

Tecfidera Captures the Largest U.S. Neurologist-Reported Patient Share Among Oral Disease-Modifying Multiple Sclerosis Therapies Ten Months Post-Launch

Read more »

Labels: Aubagio, Betaseron, Copaxone, Gilenya, TECFIDERA, Tysabri

Biogen Idec: A Biotech Pioneer With A Stellar Future

Read more »

Labels: Rituxan, TECFIDERA, Tysabri

FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments

This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY

Read more »

Labels: Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Lemtrada, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri

15 STUDIES IN FRIDAY'S NEWS

 PLUS: 1590 new Studies we posted from 11/1 to Thursday 2/12 Start at the Bottom!

The NBSS, developed specifically to assess the symptoms and consequences associated with neurogenic bladder dysfunction, has appropriate psychometric properties. Depending on the measurement need, individual domains may be selected, or it can be used as a comprehensive score.

Read Study at Pubmed.gov

The fraction of intrathecally-produced VZV-specific IgG of the total intrathecally produced IgG discriminates between patients with VZV reactivation and MS. Our results provide further evidence that intrathecally-produced VZV antibodies are part of the polyspecific immune response in patients with MS.

Read study at Pubmed.gov

 In addition to autoantigens implicated in thyroid autoimmunity, fibrocytes and derivative fibroblasts express multiple autoantigens associated with T1DM. This expression results from active gene promoters and abundant steady-state mRNA encoding ICA69 and IA-2. These latest findings demonstrate that fibrocytes express antigens relevant to multiple forms of endocrine autoimmunity. They suggest the potential for these cells playing a direct role in immune reactivity directed at the thyroid and pancreatic islets.

Read Study at Pubmed.gov

MMPs can also enhance the cleavage of myelin basic protein (MBP) and the demyelination process. Regarding the growing data on the roles of MMPs and their tissue inhibitors (TIMPs) in the pathogenesis of MS, this review discusses the role of different types of MMPs, including MMP-2, -3, -7, -9, -12 and -25, in the immunopathogenesis and treatment of MS.

Read Study at Pubmed.gov

In a real-world setting, patients with MS who switched from IFNs to fingolimod were significantly less likely to experience relapses than those who switched to GA.
Read Study Pubmed.gov

Read more »

Labels: 500 BEST PML STORIES & STUDIES, Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, PML (Progressive Multifocal Leukoencephalopathy), Rebif, Sativex, TECFIDERA, Tysabri

15 STUDIES IN MONDAY'S NEWS

 PLUS: 1530 new Studies we posted from 11/1 to Sunday 2/9 Start at the Bottom!

Farming and exposure to livestock may be important factors in the development of FCD among women, with this finding further revealed after the confounding effect of parity or number of children is considered.
Read Study at Pubmed.gov

Results suggest that demyelinated lesions in MS mainly have a remote effect on the thalamus and that the measurement of CBF using ASL could be an objective marker for monitoring disease activity in MS.
Read Study at Pubmed.gov

Here, we summarize currently accepted therapeutic principles and the drugs in late stages of development, as well as spotlighting potential novel openings for future research.
Read Study at Pubmed.gov

Collaboration between neurologists and psychiatrists whilst caring for patients displaying neuropsychiatric manifestations of MS is crucial to enable more accurate diagnoses and try to improve treatment and overall prognosis. 
Read Study at Pubmed.gov

In summary, in this retrospective analysis, daclizumab therapy substantially decreased the rate of brain atrophy in relapsing-remitting MS in comparison to other disease-modifying therapies, predominantly interferon β.
Read Study at Pubmed.gov

Read more »

Labels: Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, Rebif, Sativex, TECFIDERA, Tysabri

15 STUDIES IN SUNDAY'S NEWS

 PLUS: 1515 new Studies we posted from 11/1 to Saturday 2/8 Start at the Bottom!


In this paper we present a new unsupervised approach addressing this problem with dictionary learning and sparse coding methods. We show its general applicability to the problem of lesion segmentation by evaluating our approach on synthetic and clinical image data and comparing it to state-of-the-art methods.
Read Study at Pubmed.gov

In this paper we will review the substantial literature regarding experimental and clinical use of these stem cells and possible mechanisms in the treatment of MS. These results may pave the road for the utilization of stem cells for the treatment of MS.
Read Study at Pubmed.gov

Long walking tests and patient-reported MSWS-12 were more appropriate than short walking tests in detecting clinically meaningful improvement after physical rehabilitation, particularly the MSWS-12 for moderate to severely disabled pwMS.
Read Study at Pubmed.gov

The use of patient self-assessed outcome measures that appraise the quality of diagnosis communication is also important to allow health services to understand and meet the needs and preferences of PwMS.
Read Study at Pubmed.gov

Quantitative gait assessment reveals subtle gait disorders in patients with low disability of relapsing-remitting multiple sclerosis. The impact of different cognitive domains on gait induces specific gait disturbances that highlight the strong interaction between gait and cognition.
Read Study at Pubmed.gov

Read more »

Labels: Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, Rebif, Sativex, TECFIDERA, Tysabri